Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)

Published: Jan. 9, 2024

Language: Английский

---

Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Aug. 11, 2024

Novel therapeutic agents in clinical trials offer a paradigm shift the approach to battling this prevalent and destructive disease, area of cancer therapy is on precipice trans formative revolution. Despite importance tried-and-true treatments like surgery, radiation, chemotherapy, disease continues evolve adapt, making new, more potent methods necessary. The field currently witnessing emergence wide range innovative approaches. Immunotherapy, including checkpoint inhibitors, CAR-T cell treatment, vaccines, utilizes host's immune system selectively target eradicate malignant cells while minimizing harm normal tissue. development targeted medicines kinase inhibitors monoclonal antibodies has allowed for less harmful approaches treating cancer. With help genomics molecular profiling, "precision medicine" customizes therapies each patient's unique genetic makeup maximize efficacy unwanted side effects. Epigenetic therapies, metabolic interventions, radio-pharmaceuticals, an increasing emphasis combination with synergistic effects further broaden landscape. Multiple-stage are essential determining safety these novel drugs, allowing patients gain access also furthering scientific understanding. future rife promise, as integration artificial intelligence big data potential revolutionize early detection prevention. Collaboration among researchers, healthcare providers, active involvement remain bedrock ongoing battle against In conclusion, dynamic evolving landscape provides hope improved treatment outcomes, emphasizing patient-centered, data-driven, ethically grounded we collectively strive towards cancer-free world.

Language: Английский

---

Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy

ACS Nano, Journal Year: 2024, Volume and Issue: 18(9), P. 7136 - 7147

Published: Feb. 26, 2024

Tapping into the innate immune system's power, nanovaccines can induce tumor-specific responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design, requiring simultaneous loading of antigens and adjuvants, complex poses challenges for mass production. Here, we developed tumor nanovaccine platform that integrates adjuvant functions delivery vehicle, using branched polyguanidine (PolyGu) nanovaccines. These were produced by modifying polyethylenimine (PEI) with various guanidine groups, transforming PEI's cytotoxicity activation. The PolyGu based on poly(phenyl biguanidine ) (Poly-PBG) effectively stimulated dendritic cells, promoted their maturation

Language: Английский

---

Injectable Adhesive Hydrogel as Photothermal‐Derived Antigen Reservoir for Enhanced Anti‐Tumor Immunity

Advanced Functional Materials, Journal Year: 2021, Volume and Issue: 31(20)

Published: March 3, 2021

Abstract Low vaccine immunogenicity and tumor heterogenicity greatly limit the therapeutic effect of vaccine. In this study, a novel injectable adhesive hydrogel, based on thermosensitive nanogels containing catechol groups loaded with in situ‐forming MnO 2 nanoparticles, is constructed to overcome these issues. The concentrated nanogel dispersion transforms into an hydrogel situ after intratumoral injection. photothermal nanoparticles induces immunogenic cell death release mass autologous tumor‐derived protein antigens under near‐infrared irradiation, which act as ideal immune stimulating substances avoiding problem are captured by hydrogel. antigens‐captured acts “antigen reservoir” releases recruit more dendritic cells stimulate intensive lasting anti‐tumor response mediated CD8 + T cells. primary tumors can be almost completely disappeared within 4 days without relapse, growth distal rechallenged also effectively inhibited treatment hydrogel‐based therapy. Therefore, proposed strategy shows great potential application personalized enhancing cancer

Language: Английский

---

Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

Military Medical Research, Journal Year: 2022, Volume and Issue: 9(1)

Published: Oct. 13, 2022

Abstract Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration microenvironment. Conventional therapeutic strategies for pancreatic usually suffer resistance, highlighting the necessity personalized precise treatment. Cancer vaccines have become promising alternatives treatment because of their multifaceted advantages including multiple targeting, minimal nonspecific effects, broad window, low toxicity, induction persistent immunological memory. Multiple conventional based on cells, microorganisms, exosomes, proteins, peptides, or DNA against been developed; however, overall efficacy remains unsatisfactory. Compared with these vaccine modalities, messager RNA (mRNA)-based offer technical conceptional advances treatment, thus represent a potentially cutting-edge option novel approaches cancer. This review summarizes current progress vaccines, highlights superiority mRNA over other proposes viable tactic designing applying

Language: Английский

---

Peptides for Vaccine Development

ACS Applied Bio Materials, Journal Year: 2022, Volume and Issue: 5(3), P. 905 - 944

Published: Feb. 23, 2022

This review discusses peptide epitopes used as antigens in the development of vaccines clinical trials well future vaccine candidates. It covers peptides potential immunotherapies for infectious diseases including SARS-CoV-2, influenza, hepatitis B and C, HIV, malaria, others. In addition, cancer that target examples overexpressed proteins are summarized, human epidermal growth factor receptor 2 (HER-2), mucin 1 (MUC1), folate receptor, The uses to cancers caused by infective agents, example, cervical papilloma virus (HPV), also discussed. provides an overview model stimulate non-specific immune responses, self-adjuvanting peptides, influence other adjuvants on formulations. As highlighted this review, several advanced vaccines, there is great therapies due specificity response can be achieved using epitopes.

Language: Английский

---

Synthesis, properties, and biomedical applications of alginate methacrylate (ALMA)-based hydrogels: Current advances and challenges

Applied Materials Today, Journal Year: 2021, Volume and Issue: 24, P. 101150 - 101150

Published: Aug. 18, 2021

Alginate methacrylate (ALMA) hydrogels have been prevalently used in various biomedical applications, mainly due to their photocrosslinking ability. Not only this feature allows the formation of cell-laden hydrogels, but it also facilitates fine-tuning hydrogels' physical attributes such as mechanical properties, pore size distribution, and degradation rate. In past decade, modifications were applied ALMA amend physiochemical biological properties enhance performance tissue engineering applications. Moreover, advent microfabrication technologies further expanded horizon by facilitating fabrication microstructures with controlled architecture. Remarkably, these improvements opened up new avenues research study cell-cell interactions cell morphogenesis response microstructural cues. Aside from that, successfully for regeneration multiple tissues, including bone, cartilage, muscle, among others. Given current state on is timely map evolution review collective work topic. Herein, we provided an extensive ALMA-based covering a broad spectrum issues topic, synthesis methods, tuning organic/inorganic composites, microfabrication, Lastly, future directions regarding application developing advanced materials are discussed.

Language: Английский

---

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

Advanced Science, Journal Year: 2022, Volume and Issue: 9(23)

Published: June 16, 2022

Immune checkpoint blockade (ICB) has significantly advanced cancer immunotherapy, yet its patient response rates are generally low. Vaccines, including immunostimulant-adjuvanted peptide antigens, can improve ICB. The emerging neoantigens generated by somatic mutations elicit cancer-specific immunity for personalized immunotherapy; the novel cyclic dinucleotide (CDN) adjuvants activate stimulator of interferon genes (STING) antitumor type I (IFN-I) responses. However, CDN/neoantigen vaccine development been limited poor antigen/adjuvant codelivery. Here, pH-responsive codelivering nanovaccines (NVs) ICB combination tumor immunotherapy reported. polymers synthesized to be self-assembled into multivesicular nanoparticles (NPs) at physiological pH and disassembled acidic conditions. NPs with high CDN/antigen coloading selected as NVs codelivery antigen presenting cells (APCs) in immunomodulatory lymph nodes (LNs). In endosome APCs, facilitate release escape cytosol, where CDNs STING IFN-I responses antigens presented major histocompatibility complex (MHC) T-cell priming. mice, potent antigen-specific CD8

Language: Английский

---

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

Materials Horizons, Journal Year: 2022, Volume and Issue: 10(2), P. 361 - 392

Published: Nov. 29, 2022

Polymeric nanoparticle-based cancer vaccines with the components of antigens ( ex vivo and in situ ) different immune adjuvants.

Language: Английский

---

Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation

Chemical Society Reviews, Journal Year: 2022, Volume and Issue: 52(1), P. 47 - 96

Published: Nov. 25, 2022

This review overviews the landscape of nanomedicine-aided cancer radio-immunotherapy in a “from bench to clinic” manner.

Language: Английский

---